Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition By Investing.com

NEWTON, Mass., Nov. 18, 2024 /PRNewswire/ —  Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA.

“We are pleased to share presentations on selinexor at this year’s annual meeting,” said Reshma Rangwala, MD, PhD, Chief Medical (TASE:) Officer and Head of Research at Karyopharm. “The data being presented demonstrate our commitment, as well as that of our partners to our ongoing work in multiple myeloma and myelofibrosis.”

Details for the ASH 2024 selected Karyopharm abstracts are as follows:

Details for a selected partner presentation on Antengene’s latest data are as follows:

About XPOVIO ® (selinexor)

XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with VELCADE ® (bortezomib) and dexamethasone (XVd) in patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in patients with diffuse large B-cell lymphoma (DLBCL),…